Indeed, these findings clearly demonstrate that the immunokinase fusion protein (hCFP) termed DK1KD-SGIII specifically and efficiently killed CD22-positive cells of B-cell lymphoma lines (2 Burkitt’s, 1 FL/DLBCL, 2 CLL-derived) and primary CLL samples (IC50 ranging from 275 to 875 nM), without affecting CD22-negative cells from healthy donors or CLL-patients. The gene discussed is CD22; the disease is B-cell non-Hodgkin lymphoma.